Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

76 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Proof of concept studies for tissue-protective agents in multiple sclerosis.
Mehta LR, Schwid SR, Arnold DL, Cutter GR, Aradhye S, Balcer LJ, Calabresi PA, Cohen JA, Cole PE, Glanzman R, Goelz S, Inglese M, Kapoor R, Kappos L, Kreitman R, Lublin FD, Mann A, Marrie RA, O'Looney P, Polman CH, Ravina BM, Reingold SC, Richert JR, Sandrock AW, Waubant E. Mehta LR, et al. Among authors: goelz s. Mult Scler. 2009 May;15(5):542-6. doi: 10.1177/1352458508101939. Mult Scler. 2009. PMID: 19389749 Review.
Neutralizing antibodies and efficacy of interferon beta-1a: a 4-year controlled study.
Kappos L, Clanet M, Sandberg-Wollheim M, Radue EW, Hartung HP, Hohlfeld R, Xu J, Bennett D, Sandrock A, Goelz S; European Interferon Beta-1a IM Dose-Comparison Study Investigators. Kappos L, et al. Among authors: goelz s. Neurology. 2005 Jul 12;65(1):40-7. doi: 10.1212/01.wnl.0000171747.59767.5c. Neurology. 2005. PMID: 16009883 Clinical Trial.
A multicenter, open-label, phase II study of the immunogenicity and safety of a new prefilled syringe (liquid) formulation of Avonex in patients with multiple sclerosis.
Phillips JT, Rice G, Frohman E, Vande Gaer L, Scott T, Haas J, Eggenberger E, Freedman MS, Stuart W, Cunha L, Jacobs L, Oger J, Arnold D, Murray TJ, DiBiase M, Jethwa V, Goelz S. Phillips JT, et al. Among authors: goelz s. Clin Ther. 2004 Apr;26(4):511-21. doi: 10.1016/s0149-2918(04)90053-7. Clin Ther. 2004. PMID: 15189748 Clinical Trial.
Risk of natalizumab-associated progressive multifocal leukoencephalopathy.
Bloomgren G, Richman S, Hotermans C, Subramanyam M, Goelz S, Natarajan A, Lee S, Plavina T, Scanlon JV, Sandrock A, Bozic C. Bloomgren G, et al. Among authors: goelz s. N Engl J Med. 2012 May 17;366(20):1870-80. doi: 10.1056/NEJMoa1107829. N Engl J Med. 2012. PMID: 22591293 Free article.
Beta-interferon for multiple sclerosis.
Rudick RA, Goelz SE. Rudick RA, et al. Exp Cell Res. 2011 May 15;317(9):1301-11. doi: 10.1016/j.yexcr.2011.03.002. Epub 2011 Mar 21. Exp Cell Res. 2011. PMID: 21396360 Review.
76 results